THC

Tenet HealthcareA

NYSE / Health Care Equipment & Services

Quote time unavailable

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

25%

Probability

Target price

$310.00

Analysis reference price unavailable

Analysis 2026-09-08 · RankAlpha Sentiment Codex

Most likely

Base case

50%

Probability

Target price

$285.00

Analysis reference price unavailable

Analysis 2026-09-08 · RankAlpha Sentiment Codex

B-

Bear case

25%

Probability

Target price

$230.00

Analysis reference price unavailable

Analysis 2026-09-08 · RankAlpha Sentiment Codex

The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented

AI sentiment snapshot

Latest data as of 2026-09-08

AI commentary

Primary SEC earnings evidence is positive, but the Q2 event is dated and likely mostly priced in. The supplied feed includes a Tenet Healthcare conference item but no substantive update, and also contains unrelated Tenet Fintech Group stories that were excluded. Analyst revisions, verified market reaction, options, short-interest, employee, and social data are unavailable. This supports a cautious monitoring stance rather than an aggressive directional call.

RankAlpha Sentiment Codex - 2026-09-08

Open full AI memo

Evidence flagged

memo remains a monitoring view with limited forward evidence and should not be standard-conviction

Impact

tentative

Confidence

AI events

2026-07-23eventQ2 2026 earnings beat and raised outlookMedium impact

Tenet reported Q2 adjusted diluted EPS of $6.12, Adjusted EBITDA of $1.304 billion, and raised FY2026 Adjusted EBITDA and adjusted free-cash-flow outlooks; the board also authorized an additional $2.0 billion for repurchases [#SEC-8K-2026-07-23].

2026-12-31catalystPayer-mix pressure remains a margin swing factorMedium impact

Lower exchange admissions created unfavorable payer mix in Q2, partially offsetting same-facility revenue growth and disciplined expense management [#SEC-8K-2026-07-23].

2026-12-31catalystExecution against raised FY2026 targetsHigh impact

Delivery on the raised EBITDA and free-cash-flow ranges, supported by same-facility revenue growth and expense management, could improve earnings visibility and support capital returns [#SEC-8K-2026-07-23].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-09-08 • Updated nightlySource: Internal modelMethodology